The estimated Net Worth of George F Tidmarsh is at least $169 mil dollars as of 19 September 2019. George Tidmarsh owns over 151,291 units of Odonate Therapeutics Inc stock worth over $169,446 and over the last 14 years George sold ODT stock worth over $0.
Sign up
George Tidmarsh ODT stock SEC Form 4 insiders trading
George has made over 12 trades of the Odonate Therapeutics Inc stock since 2014, according to the Form 4 filled with the SEC. Most recently George exercised 151,291 units of ODT stock worth $169,446 on 19 September 2019.
The largest trade George's ever made was exercising 151,291 units of Odonate Therapeutics Inc stock on 19 September 2019 worth over $169,446. On average, George trades about 4,893 units every 47 days since 2010. As of 19 September 2019 George still owns at least 151,291 units of Odonate Therapeutics Inc stock.
You can see the complete history of George Tidmarsh stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
What's George Tidmarsh's mailing address?
George's mailing address filed with the SEC is C/O ODONATE THERAPEUTICS, INC., 4747 EXECUTIVE DRIVE, SUITE 510, SAN DIEGO, CA, 92121.
Insiders trading at Odonate Therapeutics Inc
Over the last 7 years, insiders at Odonate Therapeutics Inc have traded over $20,636,060 worth of Odonate Therapeutics Inc stock and bought 10,839,138 units worth $199,522,296 . The most active insiders traders include Capital, Llc Eco R1, Aaron I. Davis y Kevin Ctang Capital Partner.... On average, Odonate Therapeutics Inc executives and independent directors trade stock every 26 days with the average trade being worth of $444,503. The most recent stock trade was executed by Capital, Llc Eco R1 on 1 December 2021, trading 5,887,610 units of ODT stock currently worth $9,714,557.
What does Odonate Therapeutics Inc do?
Odonate Therapeutics, Inc. is a pharmaceutical company dedicated to the development of best-in-class therapeutics that improve and extend the lives of patients with cancer. Odonate’s initial focus is on the development of tesetaxel, an investigational, orally administered chemotherapy agent that belongs to a class of drugs known as taxanes, which are widely used in the treatment of cancer. Odonate’s goal for tesetaxel is to develop an effective chemotherapy choice for patients that provides quality-of-life advantages over current alternatives.
What does Odonate Therapeutics Inc's logo look like?
Complete history of George Tidmarsh stock trades at Anavex Life Sciences, La Jolla Pharmaceutical Co, Spectrum Pharmaceuticals y Odonate Therapeutics Inc
Odonate Therapeutics Inc executives and stock owners
Odonate Therapeutics Inc executives and other stock owners filed with the SEC include:
-
Joseph O'Connell,
Chief Medical Officer -
John Lemkey,
Chief Operating Officer -
Dr. Joseph P. O'Connell M.D.,
Chief Medical Officer -
Craig Johnson,
Independent Director -
Laura Douglass,
Independent Director -
Robert Rosen,
Director -
Kevin Tang,
Chairman of the Board, Chief Executive Officer -
Aaron Davis,
Independent Director -
Michael Hearne,
Chief Financial Officer -
Kim Ma,
Sr. VP of Clinical Operations -
Jennifer Schroeder,
Sr. VP of Program Management & Technology -
Tracey McKennon,
Sr. VP of Quality Assurance -
Stewart M. Kroll,
Chief Devel. Officer -
Thomas Wei,
Chief Scientific Officer -
Dr. Steven S. Pfeiffer Ph.D.,
Sr. VP of Technical Operations -
Ryan Cole,
Sr. VP of Operations -
Jeff L Vacirca,
Director -
Capital, Llc Boxer Asset Ma...,
-
George F Tidmarsh,
Director -
Robert D Millham,
Chief Operating Officer -
John G Lemkey,
Chief Operating Officer -
Laura L. Johnson,
Director -
Kevin Ctang Capital Partner...,
Chief Executive OfficerChief Operating OfficerChief Financial Officer -
Capital, Llc Boxer,
10% owner -
Kevin Ctang Capital Partner...,
Chief Executive OfficerChief Financial Officer -
Capital, Llc Eco R1,
10% owner